ExpreS2ion Biotech Holding AB - Asset Resilience Ratio
ExpreS2ion Biotech Holding AB (EXPRS2) has an Asset Resilience Ratio of 5.64% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See EXPRS2 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2023)
This chart shows how ExpreS2ion Biotech Holding AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of ExpreS2ion Biotech Holding AB.
Liquid Assets Composition Over Time
This chart breaks down ExpreS2ion Biotech Holding AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read ExpreS2ion Biotech Holding AB balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 0% |
| Short-term Investments | Skr4.44 Million | 5.64% |
| Total Liquid Assets | Skr4.44 Million | 5.64% |
Asset Resilience Insights
- Limited Liquidity: ExpreS2ion Biotech Holding AB maintains only 5.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ExpreS2ion Biotech Holding AB Industry Peers by Asset Resilience Ratio
Compare ExpreS2ion Biotech Holding AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for ExpreS2ion Biotech Holding AB (2018–2023)
The table below shows the annual Asset Resilience Ratio data for ExpreS2ion Biotech Holding AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 5.64% | Skr4.44 Million ≈ $477.49K |
Skr78.69 Million ≈ $8.47 Million |
+6.75pp |
| 2022-12-31 | -1.12% | Skr-1.53 Million ≈ $-164.87K |
Skr137.36 Million ≈ $14.78 Million |
-68.09pp |
| 2021-12-31 | 66.97% | Skr101.77 Million ≈ $10.95 Million |
Skr151.96 Million ≈ $16.35 Million |
+67.79pp |
| 2020-12-31 | -0.81% | Skr-966.00K ≈ $-103.96K |
Skr118.86 Million ≈ $12.79 Million |
+4.17pp |
| 2019-12-31 | -4.99% | Skr-933.00K ≈ $-100.41K |
Skr18.71 Million ≈ $2.01 Million |
-1.73pp |
| 2018-12-31 | -3.25% | Skr-682.00K ≈ $-73.39K |
Skr20.95 Million ≈ $2.25 Million |
-- |
About ExpreS2ion Biotech Holding AB
ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company's lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vacci… Read more